BG105471A - Method for preventing or delaying the need for a catheter of the coronary artery - Google Patents

Method for preventing or delaying the need for a catheter of the coronary artery

Info

Publication number
BG105471A
BG105471A BG105471A BG10547101A BG105471A BG 105471 A BG105471 A BG 105471A BG 105471 A BG105471 A BG 105471A BG 10547101 A BG10547101 A BG 10547101A BG 105471 A BG105471 A BG 105471A
Authority
BG
Bulgaria
Prior art keywords
coronary artery
catheter
need
delaying
preventing
Prior art date
Application number
BG105471A
Other languages
Bulgarian (bg)
English (en)
Inventor
Donald BLACK
Original Assignee
Warner-Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22289955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG105471(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc
Publication of BG105471A publication Critical patent/BG105471A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Surgical Instruments (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
BG105471A 1998-09-30 2001-04-25 Method for preventing or delaying the need for a catheter of the coronary artery BG105471A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10245798P 1998-09-30 1998-09-30
PCT/US1999/015385 WO2000018395A1 (en) 1998-09-30 1999-07-08 Method for preventing or delaying catheter-based revascularization

Publications (1)

Publication Number Publication Date
BG105471A true BG105471A (en) 2001-12-31

Family

ID=22289955

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105471A BG105471A (en) 1998-09-30 2001-04-25 Method for preventing or delaying the need for a catheter of the coronary artery

Country Status (35)

Country Link
US (1) US20080119561A1 (hu)
EP (1) EP1117392B1 (hu)
JP (1) JP2002525321A (hu)
KR (1) KR20010079955A (hu)
CN (1) CN1197565C (hu)
AP (1) AP1708A (hu)
AT (1) ATE260100T1 (hu)
AU (1) AU768474B2 (hu)
BG (1) BG105471A (hu)
BR (1) BR9914098A (hu)
CA (1) CA2343299C (hu)
CZ (1) CZ20011035A3 (hu)
DE (1) DE69915084T2 (hu)
DK (1) DK1117392T3 (hu)
EA (1) EA007427B1 (hu)
EE (1) EE200100199A (hu)
ES (1) ES2214872T3 (hu)
HK (1) HK1042436A1 (hu)
HR (1) HRP20010236A2 (hu)
HU (1) HUP0103648A3 (hu)
ID (1) ID30255A (hu)
IL (2) IL141953A0 (hu)
IS (1) IS5889A (hu)
NO (1) NO20011615L (hu)
NZ (1) NZ510500A (hu)
OA (1) OA11787A (hu)
PL (1) PL346980A1 (hu)
PT (1) PT1117392E (hu)
SI (1) SI1117392T1 (hu)
SK (1) SK4122001A3 (hu)
TR (1) TR200100901T2 (hu)
UA (1) UA73292C2 (hu)
WO (1) WO2000018395A1 (hu)
YU (1) YU23901A (hu)
ZA (1) ZA200102230B (hu)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001256278A1 (en) * 2000-04-18 2001-10-30 Bayer Aktiengesellschaft Use of cse inhibitors for treating heart failure
KR20030023698A (ko) * 2000-07-14 2003-03-19 워너-램버트 캄파니 카르복시알킬에테르를 사용하여 섭식 장애를 치료하는 방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5157025A (en) * 1991-04-01 1992-10-20 E. R. Squibb & Sons, Inc. Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
US5807388A (en) * 1994-05-25 1998-09-15 The Trustees Of Columbia University In The City Of New York Myocardial revascularization through the endocardial surface using a laser
WO1995013063A1 (en) * 1993-11-09 1995-05-18 Merck & Co., Inc. HMG-CoA REDUCTASE INHIBITORS IN THE NORMALIZATION OF VASCULAR ENDOTHELIAL DYSFUNCTION
US5545628A (en) * 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
US5648387A (en) * 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
EA000514B1 (ru) * 1995-11-02 1999-10-28 Варнер-Ламберт Компани Способ нормализации липопротеидного профиля плазмы крови у млекопитающего и фармацевтическая композиция для его осуществления
SE506272C2 (sv) * 1996-03-18 1997-11-24 Paul Edholm Förfarande och anordning för att bestämma bildläge och bildvinkel i en röntgenbild
IL117702A0 (en) * 1996-03-28 1996-07-23 Tel Aviv Medical Center Resear Drug for hyperlipoproteinemia
WO1998001100A2 (en) * 1996-07-09 1998-01-15 Merck & Co., Inc. Method for treating homozygous familial hypercholesterolemia
US5861399A (en) * 1996-07-17 1999-01-19 Heart Care Partners Methods and compositions for the rapid and enduring relief of inadequate myocardial function
US6180660B1 (en) * 1997-08-26 2001-01-30 Merck & Co., Inc. Cholesterol-lowering therapy
NZ503982A (en) * 1997-12-12 2002-03-28 Warner Lambert Co Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus

Also Published As

Publication number Publication date
DK1117392T3 (da) 2004-06-14
EA007427B1 (ru) 2006-10-27
CN1197565C (zh) 2005-04-20
AP1708A (en) 2007-01-10
CN1342072A (zh) 2002-03-27
AU768474B2 (en) 2003-12-11
US20080119561A1 (en) 2008-05-22
SK4122001A3 (en) 2002-06-04
UA73292C2 (en) 2005-07-15
NZ510500A (en) 2003-10-31
OA11787A (en) 2005-07-26
NO20011615L (no) 2001-04-24
HRP20010236A2 (en) 2002-04-30
BR9914098A (pt) 2001-07-31
ATE260100T1 (de) 2004-03-15
DE69915084T2 (de) 2004-07-22
IS5889A (is) 2001-03-14
NO20011615D0 (no) 2001-03-29
HK1042436A1 (en) 2002-08-16
CA2343299C (en) 2008-04-01
PT1117392E (pt) 2004-07-30
YU23901A (sh) 2003-07-07
DE69915084D1 (de) 2004-04-01
IL141953A (en) 2006-07-05
AP2001002112A0 (en) 2001-06-30
EA200100370A1 (ru) 2001-10-22
SI1117392T1 (en) 2004-06-30
ES2214872T3 (es) 2004-09-16
KR20010079955A (ko) 2001-08-22
EE200100199A (et) 2002-06-17
EP1117392A1 (en) 2001-07-25
ZA200102230B (en) 2002-06-18
JP2002525321A (ja) 2002-08-13
ID30255A (id) 2001-11-15
EP1117392B1 (en) 2004-02-25
CZ20011035A3 (cs) 2001-10-17
CA2343299A1 (en) 2000-04-06
PL346980A1 (en) 2002-03-11
HUP0103648A3 (en) 2003-10-28
AU4975099A (en) 2000-04-17
TR200100901T2 (tr) 2001-08-21
IL141953A0 (en) 2002-03-10
HUP0103648A2 (hu) 2003-08-28
WO2000018395A1 (en) 2000-04-06

Similar Documents

Publication Publication Date Title
AU1927399A (en) Catheter apparatus for treating arterial occlusions
AU1941301A (en) Implantable nickel-free stainless steel stents
IL130931A0 (en) Small molecules useful in the treatment of inflammatory disease
AU2001276952A1 (en) Method of treating the syndrome of coronary heart disease risk factors in humans
ZA9610543B (en) Compounds and compositions for reducing blood glucose and/or inhibiting the activity of CGRP.
AU3632497A (en) Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
AU2004999A (en) Catheter apparatus for guided transvascular treatment of arterial occlusions
GEP20094818B (en) 2-methyl-thieno-benzodiaze-pine formulation
AU3364499A (en) Method for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders
AU6425800A (en) Agents for the diagnosis, prognosis and treatment of malignant diseases
DE69533876D1 (de) Zusammensetzung für die gentherapeutische Behandlung von Koronar-Arterienerkrankungen.
BG105471A (en) Method for preventing or delaying the need for a catheter of the coronary artery
AU5880596A (en) Methods and compounds for diagnosing coronary artery disease
AU1476901A (en) Methods for regulating blood glucose and appetite suppression in type 2 diabetics
AU2002215187A1 (en) S-adenosylmethionine and derivatives thereof for the treatment and prevention ofalzheimer's disease
ZA997446B (en) Lowering blood levels of lipoprotein(a).
HU9300243D0 (en) 1-(b-d-arabino-furanosyl)-5-propinyl-uracyl compounds
AU2899099A (en) Composition for treatment and prevention of coronary artery disease
EP1089732A4 (en) COMPOSITIONS AND METHODS FOR TREATING INCREASED BLOOD CHOLESTEROL LEVELS
AU2002363227A1 (en) Methods for the treatment and diagnosis of tumorigenic and angiogenic disorders using 32616
FR2786685B1 (fr) Extenseurs vasculaires et coronaires, habituellement designes sous le nom de "stent"
AU6845600A (en) Method for identifying an individual at risk for vascular and cancer disease
EP1321146A3 (en) Inhibitors of type 5 and 3 17beta-hydroxysteroid dehydrogenase and methods for their use
GB9817174D0 (en) Compositions and methods for treating elevated blood cholesterol
GB9817167D0 (en) Compositions and methods for treating elevated blood cholesterol